WallStreetZenWallStreetZen

NASDAQ: SYRS
Syros Pharmaceuticals Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

SYRS past revenue growth

How has SYRS's revenue growth performed historically?
Company
-33.23%
Industry
151.46%
Market
17.61%
SYRS's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
SYRS's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
SYRS's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

SYRS earnings and revenue history

Current Revenue
$9.9M
Current Earnings
-$164.6M
Current Profit Margin
-1,656.3%

SYRS Return on Equity

Current Company
-282.6%
Current Industry
-63.5%
Current Market
188%
SYRS's Return on Equity (-282.6%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when SYRS announces earnings.

SYRS Return on Assets

Current Company
-93.7%
Current Industry
2.9%
SYRS is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

SYRS Return on Capital Employed

Current Company
-121.26%
Current Industry
19.5%
SYRS's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

SYRS vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
SYRS$9.94M-$157.12M-$164.57M+37.12%N/A
SGMT$2.00M-$27.74M-$27.88MN/AN/A
MOLN$8.00M-$61.83M-$70.44M-20.54%N/A
COYA$6.00M-$7.24M-$7.99MN/AN/A
VTGN$1.04M-$31.51M-$32.07M+84.79%N/A
View Top Biotech Stocks

SYRS earnings dates

Next earnings date
May 8, 2024

Syros Pharmaceuticals Earnings & Revenue FAQ

What were SYRS's earnings last quarter?

On Invalid Date, Syros Pharmaceuticals (NASDAQ: SYRS) reported Q4 2023 earnings per share (EPS) of -$2.22, up 150% year over year. Total Syros Pharmaceuticals earnings for the quarter were -$64.38 million. In the same quarter last year, Syros Pharmaceuticals's earnings per share (EPS) was $4.44.

If you're new to stock investing, here's how to buy Syros Pharmaceuticals stock.

What was SYRS's earnings growth in the past year?

As of Q2 2024, Syros Pharmaceuticals's earnings has grown year over year. Syros Pharmaceuticals's earnings in the past year totalled -$164.57 million.

What is SYRS's earnings date?

Syros Pharmaceuticals's earnings date is Invalid Date. Add SYRS to your watchlist to be reminded of SYRS's next earnings announcement.

What was SYRS's revenue last quarter?

On Invalid Date, Syros Pharmaceuticals (NASDAQ: SYRS) reported Q4 2023 revenue of $386.00 thousand up 151.19% year over year. In the same quarter last year, Syros Pharmaceuticals's revenue was -$754.00 thousand.

What was SYRS's revenue growth in the past year?

As of Q2 2024, Syros Pharmaceuticals's revenue has grown -33.23% year over year. This is 184.68 percentage points lower than the US Biotechnology industry revenue growth rate of 151.46%. Syros Pharmaceuticals's revenue in the past year totalled $9.94 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.